Novartis Ag (NVS) Cash from Investing Activities Growth (1y) (2010 - 2025)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
-16.79% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-250.17% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
21.90% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
73.75% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Dec 31, 2025 |
48.76% |
| Sep 30, 2025 |
-129.95% |
| Jun 30, 2025 |
30.06% |
| Jun 30, 2024 |
-204.56% |
| Jun 30, 2023 |
90.94% |
| Jun 30, 2022 |
-12,087.63% |
| Dec 31, 2021 |
1,019.79% |
| Jun 30, 2021 |
122.82% |
| Dec 31, 2020 |
-279.56% |
| Jun 30, 2020 |
10.34% |
| Dec 31, 2019 |
108.08% |
| Jun 30, 2019 |
-110.96% |
| Dec 31, 2018 |
-294.98% |
| Sep 30, 2018 |
-29.34% |
| Jun 30, 2018 |
1,383.38% |
| Dec 31, 2017 |
-17.59% |
| Sep 30, 2017 |
0.58% |
| Jun 30, 2017 |
43.17% |
| Sep 30, 2016 |
-12.40% |
| Sep 30, 2015 |
-1,135,185,285.19% |
| Dec 31, 2014 |
-1,505.36% |
| Sep 30, 2014 |
107.17% |
| Jun 30, 2014 |
-29.50% |
| Jun 30, 2013 |
17.01% |
| Mar 31, 2013 |
256.40% |
| Jun 30, 2012 |
-757.27% |
| Mar 31, 2012 |
-190.63% |
| Dec 31, 2011 |
-40.37% |
| Mar 31, 2011 |
143.22% |
| Dec 31, 2010 |
86.00% |
| Mar 31, 2010 |
60.03% |
